Q32 Bio Inc. (QTTB) EBIT (2017 - 2026)

Q32 Bio has reported EBIT for 10 years, with the latest figure at -$9.1 million in Q2 2026.

• On a quarterly basis, EBIT rose 0.58% year-over-year to -$9.1 million in Q2 2026; TTM through Jun 2026 was $21.5 million, a 139.21% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, up 125.57% from the prior year.
• EBIT was -$9.1 million for Q2 2026 at Q32 Bio, down from -$7.7 million in the prior quarter.
• The five-year high for EBIT was $45.9 million in Q4 2025, with the low at -$37.6 million in Q1 2022.
• Average EBIT over 5 years is -$13.8 million, with a median of -$13.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: EBIT slumped 3285.96% in 2022, then surged 415.84% in 2025.
• Over 5 years, EBIT stood at -$34.5 million in 2022, then increased by 25.18% to -$25.8 million in 2023, then soared by 43.72% to -$14.5 million in 2024, then soared by 415.84% to $45.9 million in 2025, then plunged by 119.87% to -$9.1 million in 2026.
• The last three EBIT figures came in at -$9.1 million (Q2 2026), -$7.7 million (Q1 2026), and $45.9 million (Q4 2025), per Business Quant data.